HLA-A2-restricted peptide epitopes of fibroblast activation protein alpha (FAPα) for cancer vaccination

The following invention is a new, peptide based vaccination against genetical stable tumor stroma-associated antigens. Because of significant upregulation of certain proteins (e.g. FAPα, CD105) tumor stroma cells are suitable targets for anti-tumor therapy. This technology employs these specific antigens in the vaccine design to avoid an immunologic attack on normal unaltered cells.

Further Information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Red light therapy for repairing spinal cord injury passes milestone

Patients with spinal cord injury (SCI) could benefit from a future treatment to repair nerve connections using red and near-infrared light. The method, invented by scientists at the University of…

Insect research is revolutionized by technology

New technologies can revolutionise insect research and environmental monitoring. By using DNA, images, sounds and flight patterns analysed by AI, it’s possible to gain new insights into the world of…

X-ray satellite XMM-newton sees ‘space clover’ in a new light

Astronomers have discovered enormous circular radio features of unknown origin around some galaxies. Now, new observations of one dubbed the Cloverleaf suggest it was created by clashing groups of galaxies….

Partners & Sponsors